The nefIgArd clinical research study is for patients diagnosed with primary IgA Nephropathy, IgAN, who are at risk of developing end-stage kidney disease even though they are taking medication to preserve kidney function. IgAN, also known as Berger’s disease, is a kidney disease where the antibody called immunoglobulin A, IgA, embeds itself into the kidneys. This causes inflammation, which can affect the kidney’s ability to filter the blood. Some cases of IgAN progress slowly without symptoms or go into remission, while others lead to end-stage kidney failure. Currently, there are no drugs approved specifically to treat IgAN. The purpose of the nefIgArd study is to look at the safety, tolerability, and effectiveness of the study drug Nefecon compared to placebo in patients with IgAN, who are at risk of progressing to end-stage kidney disease To learn more about study participation, contact: Ciara Mitchell at 205-975-9491.
You may qualify to participate in a 4-month research study, funded by the National Institute of Health (NIH), on blood vessel health in patients with chronic kidney disease. Qualifying participants must: Be between the ages of 19 and 65 Not on Dialysis Have moderate stage of kidney disease with 26%-60% function. Participants will be compensated. For more information, please contact UAB Division of Nephrology at 205-934-7295. Or email Salam Madi salammadi@uabmc.edu
Do you have Kidney Disease? You may qualify to participate in a 4-month research study, funded by the National Institute of Health (NIH), on blood vessel health in patients with chronic kidney disease. Qualifying participants must, 1. Be between the ages of 19 and 65, 2. Not on Dialysis, 3. Have a moderate stage of kidney disease (25-60% function). Participants will be compensated. For more information, please contact UAB Division of Nephrology 205-934-7295. Or email Salam Madi at salammadi@uabmc.edu
We are looking for healthy men and women ages 18-65 to participate in a research study. You must have no history of gastrointestinal or kidney disease. We are conducting a study to examine the presence of Oxalobacter, a naturally occurring molecule in our bodies. This study involves collection of stool specimens. Compensation is provided. Please send an email to kidneystone@uabmc.edu if you are interested.
The UAB Department of Nutrition Sciences is conducting a research study to evaluate the effectiveness of an investigational drug to treat Type 2 DM. To qualify, you must be 18 years old or older, diagnosed with type 2 diabetes, kidney disease and have risk factors for a cardiovascular event (such as heart attack and stroke). Qualified participants will receive study drug, diet/exercise counseling, EKG, physical and diabetic supplies. There is no charge for participation. Compensation for time and travel may also be available. For more information, and to see if you might be eligible to join, please contact (205)975-8217 or (205)996-4020.
You may qualify to participate in an international research study to evaluate the safety and tolerability of an investigational drug for patients with type 2 diabetes and kidney disease. Are you at least 18 years old? Do you have type 2 diabetes mellitus and a clinical diagnosis of kidney disease? Eligible study participants will receive study medications, blood pressure checks, physical exams, laboratory tests and ECG at no cost. Participants will  be reimbursed for time and travel. For more information, call the UAB Hypertension Program at 934-9281 or e-mail ccc-hlnresearch@mail.ad.uab.edu.